Treace Medical Concepts, Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

SAN DIEGO, May 12, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential claims on behalf of investors of Treace Medical Concepts, Inc. (NASDAQ: TMCI). The investigation focuses on Treace’s executive officers and whether investor losses may be recovered under federal securities laws.

What if I purchased Treace securities?
If you purchased Treace securities and suffered losses on your investment, join our investigation now: Click here to join the investigation.

Or for more information, contact Jim Baker at jimb@johnsonfistel.com or (619) 814-4471.

There is no cost or obligation to you.

Background of the investigation
On November 6, 2025, Treace reported its third quarter 2025 financial results and revised its full-year 2025 outlook.

Treace disclosed that its revenue growth reflected “higher than planned sales to a limited number of stocking distributors” that the Company did “not expect to recur at the same level.” The Company further disclosed that Lapiplasty volumes had been impacted as surgeon and patient preferences shifted toward minimally invasive solutions, and that broader macroeconomic conditions and softer consumer sentiment were resulting in more deferrals of elective bunion procedures.

In its quarterly report, Treace further disclosed that third quarter revenue growth was partially offset by lower average selling prices of its newest bunion procedure kits, and that third quarter revenue included $6.0 million in sales to stocking distributors, a majority of which was attributable to initial stocking orders.

In addition, Treace lowered its full-year 2025 revenue guidance to a range of $211 million to $213 million, compared to previous guidance of $224 million to $230 million. The Company stated that the reduction was primarily the result of expected lower sales from its flagship Lapiplasty System due to evolving surgeon preferences for minimally invasive osteotomy procedures, competition, lower patient demand for elective bunion surgery due to macroeconomic conditions, and other disclosed headwinds.

Following these disclosures, Treace’s stock price declined sharply, damaging investors.

In light of this disclosure, Johnson Fistel is investigating whether Treace complied with the federal securities laws. If you suffered losses from your investment in Treace stock, contact Johnson Fistel.

About Johnson Fistel, PLLP | Securities Fraud & Investor Rights
Johnson Fistel, PLLP is a nationally recognized shareholder-rights law firm with offices in California, New York, Georgia, Idaho, and Colorado. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits and also assists foreign investors who purchased shares on U.S. exchanges. To learn more, visit www.johnsonfistel.com.

Achievements
In 2024, Johnson Fistel was ranked among the Top 10 Plaintiff Law Firms by ISS Securities Class Action Services, reflecting the firm’s effectiveness in advocating for investors and recovering approximately $90,725,000 for clients in cases where it served as lead or co-lead counsel.

Attorney advertising.
Past results do not guarantee future outcomes.
Services may be performed by attorneys in any of our offices.
Johnson Fistel, PLLP has paid for the dissemination of this promotional communication, and Frank J. Johnson is the attorney responsible for its content.

Contact
Johnson Fistel, PLLP
501 W. Broadway, Suite 800
San Diego, CA 92101
James Baker, Investor Relations – or – Frank J. Johnson, Esq.
(619) 814-4471 | jimb@johnsonfistel.com

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.